1. Home
  2. DLNG vs ENTX Comparison

DLNG vs ENTX Comparison

Compare DLNG & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dynagas LNG Partners LP

DLNG

Dynagas LNG Partners LP

HOLD

Current Price

$3.93

Market Cap

139.0M

ML Signal

HOLD

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.45

Market Cap

74.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLNG
ENTX
Founded
2013
2010
Country
Greece
Israel
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
139.0M
74.7M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
DLNG
ENTX
Price
$3.93
$1.45
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$10.00
AVG Volume (30 Days)
114.2K
92.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
5.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.18
Revenue
N/A
$181,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$0.37
N/A
P/E Ratio
$3.04
$7.56
Revenue Growth
N/A
N/A
52 Week Low
$3.18
$1.00
52 Week High
$4.45
$3.22

Technical Indicators

Market Signals
Indicator
DLNG
ENTX
Relative Strength Index (RSI) 47.19 50.57
Support Level $3.46 $1.17
Resistance Level $4.16 $1.72
Average True Range (ATR) 0.22 0.15
MACD -0.03 0.01
Stochastic Oscillator 23.77 59.52

Price Performance

Historical Comparison
DLNG
ENTX

About DLNG Dynagas LNG Partners LP

Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.

Share on Social Networks: